Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beersheba
Clinical trial register · Israel

Clinical Trials in Beersheba, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2438 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2438
Studies in scope
all four open statuses
1243
Recruiting now
open to new participants
461
Lead sponsors
across recruiting studies
Top sites
Jerusalem 848 Haifa 738 Tel Aviv 691 Ramat Gan 653 Petah Tikva 619
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company21 Merck Sharp & Dohme LLC19 AbbVie18 AstraZeneca13 Hoffmann-La Roche12
Site location
Jerusalem848 Haifa738 Tel Aviv691 Ramat Gan653 Petah Tikva619
All 102 locations
Target enrolment
to

Trials with a site in Beersheba

252 of 2438 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Not yet open
Rewiring Chronic Pain
NCT07724808Full PRT, Partial PRT (Non Somtic), Treatment as Usual
Ben-Gurion University of the Negev
Not applicable
150
Beersheba
2026-10-01
Not yet open
Deep TMS for PTSD With Suicidal Ideation
NCT07880340Post Traumatic Stress Disorder PTSD, Suicidal Ideation
D.R. Rut Zaks OHAYON
Not applicable
72
Beersheba
2026-10
Recruiting
Eli Lilly and Company
Phase 3
150
Beer Jacob, Beersheba, Haifa, Jerusalem, Petah Tikva
2026-09-25
Not yet open
Barzilai Medical Center
Not applicable
500
Ashdod, Ashkelon, Beersheba
2026-09-01
Recruiting
Novo Nordisk A/S
Phase 3
80
Afula, Beersheba, Haifa, Jerusalem
2026-08-04
Recruiting
Boehringer Ingelheim
Phase 3
390
Beersheba, Haifa, Jerusalem, Tel Aviv
2026-07-10
Active, closed
Comparison Between Paravertebral and Erector Spinal Block Efficacy in Robotic Thoracic Surgeries
NCT07782073Post Operative Analgesia, Regional Anaesthesia, Pain After Surgery, Opioid Consumption
Soroka University Medical Center
Not applicable
60
Beersheba
2026-07-01
Recruiting
BIO|STREAM.CSP Study
NCT07393009Cardiac Pacing, Cardiac Pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy Devices
Biotronik SE & Co. KG
Observational
1,000
Ashdod, Beersheba, Hadera, Jerusalem, Tel Aviv
2026-05-25
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan
2026-05-11
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Afula, Ashdod, Beer Yaakov, Beersheba, Hadera, Haifa, Holon, Jerusalem
2026-05-11
Recruiting
Eli Lilly and Company
Phase 3
900
Afula, Atlit, Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
300
Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Beersheba, Haifa, Jerusalem, Ramat Gan, Ramat Poriya, Tel Aviv
2026-02-04
By invitation
Immunovant Sciences GmbH
Phase 2
372
Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2026-01-26
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 3
80
Beersheba, Haifa
2026-01-14
Recruiting
Eli Lilly and Company
Phase 3
150
Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2026-01-12
Recruiting
AstraZeneca
Phase 3
1,100
Afula, Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya
2025-12-29
Recruiting
Sheba Medical Center
Phase 2
168
Beersheba, Pardesiyya
2025-12-24
Recruiting
Eli Lilly and Company
Phase 3
7,140
Ashdod, Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva
2025-12-01
Recruiting
Beersheva Mental Health Center
Phase 2
20
Beersheba
2025-12-01
Recruiting
Novartis Pharmaceuticals
Phase 3
31
Beersheba, Haifa, Jerusalem, Petah Tikva
2025-11-27
Not yet open
Home-Based Language and Cognitive Intervention for Arab Toddlers in Israel
NCT07233525Enhancing Early Language and Cognitive Development in Toddlers Through a Culturally Adapted Home-based Parent Intervention
Hillel Yaffe Medical Center
Not applicable
240
Beersheba
2025-11-20
Recruiting
Brainsway
Not applicable
186
Beersheba
2025-11-07
Recruiting
GlaxoSmithKline
Phase 2
363
Ashdod, Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Koranit, Petah Tikva
2025-10-30
Recruiting
Eli Lilly and Company
Phase 3
4,500
Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 3
424
Hod HaSharon, Ramat Gan, Ashkelon, Beersheba, Jerusalem
2025-10-08
Recruiting
Sanofi
Phase 3
980
Afula, Ashkelon, Beersheba, Jerusalem, Nahariya, Petah Tikva, Tel Aviv
2025-10-01
Recruiting
Sanofi
Phase 3
942
Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
2025-09-17
Recruiting
AstraZeneca
Phase 3
700
Afula, Beersheba, Hadera, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva
2025-08-06
Recruiting
Mapi Pharma Ltd.
Phase 1/2
24
Beersheba, Ness Ziona, Ramat Gan, Tel Aviv
2025-08-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Beersheba, Haifa, Jerusalem, Ramat Gan
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
450
Hod HaSharon, Ness Ziona, Petah Tikva, Ramat Gan, Beersheba, Ashkelon, Jerusalem
2025-07-18
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Afula, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan
2025-07-03
Recruiting
AbbVie
Phase 1/2
602
Petah Tikva, Beersheba, Ramat Gan, Haifa, Jerusalem
2025-06-30
Recruiting
GlaxoSmithKline
Phase 3
961
Ashkelon, Beer-Yaakov, Beersheba, Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva
2025-06-23
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Ramat Gan, Haifa, Nahariya, Tzfat, Beersheba, Jerusalem, Kfar Saba, Petah Tikva
2025-06-19
Active, closed
AbbVie
Phase 3
573
Petah Tikva, Tsrifin, Ashdod, Beersheba, Ramat Gan, Tel Aviv, Haifa
2025-06-17
Recruiting
Bristol-Myers Squibb
Phase 3
274
Hod HaSharon, Ness Ziona, Petah Tikva, Ramat Gan, Beersheba, Jerusalem
2025-06-13
Recruiting
MediWound Ltd
Phase 3
216
Petah Tikva, Nahariya, Beersheba, Be’er Ya‘aqov, Ramat Gan, Rehovot
2025-06-01
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Beer Yaaqov, Beersheba, Haifa, Jerusalem, Nahariya
2025-05-27
Recruiting
Eikon Therapeutics
Phase 2/3
740
Beersheba, Petah Tikva, Ramat Gan, Tel Aviv
2025-05-22
Active, closed
Eli Lilly and Company
Phase 3
905
Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2025-04-25
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
2025-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv
2025-04-11
Recruiting
AstraZeneca
Phase 3
830
Afula, Beersheba, Hadera, Haifa, Jerusalem, Ramat Gan, Tel Aviv
2025-04-10
Recruiting
Gilead Sciences
Phase 3
695
Beersheba, Haifa, Jerusalem, Kfar Saba, Naharyia
2025-04-04
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2/3
150
Haifa, Beersheba
2025-03-25
Recruiting
Hoffmann-La Roche
Phase 3
600
Beersheba, Haifa, Jerusalem, Ramat Gan
2025-03-17
Recruiting
AstraZeneca
Phase 3
11,300
Beersheba, Be’er Ya‘aqov, Haifa, Herzelia, Holon, Jerusalem, Petah Tikva, Ramat Gan
2025-03-14
Recruiting
University of Erlangen-Nürnberg Medical School
Not applicable
127
Beersheba
2025-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2025-02-27
Recruiting
Dianthus Therapeutics
Phase 3
256
Beersheba, Haifa, Safed
2025-02-10
Active, closed
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
875
Ashkelon, Beer Jacob, Beersheba, Haifa, Jerusalem
2025-02-05
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Beersheba, Jerusalem, Petah Tikva, Tel Aviv
2025-01-28
Recruiting
Ben-Gurion University of the Negev
Not applicable
160
Beersheba
2025-01-25
Recruiting
Takeda
Phase 3
396
Beersheba, Haifa, Kfar Saba, Petah Tikva, Tel Aviv
2025-01-02
Recruiting
GlaxoSmithKline
Phase 3
520
Beersheba, Jerusalem, Koranit, Petah Tikva, Tel Aviv
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Beersheba, Haifa, Kfar Saba, Ramat Gan
2024-12-16
Active, closed
Amorphical Ltd.
Phase 2
62
Ashdod, Haifa, Jerusalem, Petah Tikva, Ashkelon, Beersheba, Ramat Gan, Rehovot
2024-12-15
Active, closed
AbbVie
Phase 2
185
Kefar Sava, Beersheba, Tel Aviv, Jerusalem
2024-12-13
Active, closed
Hoffmann-La Roche
Phase 3
350
Beersheba, Ramat Gan
2024-12-11
Active, closed
Soroka University Medical Center
Observational
98
Beersheba
2024-12-01
Recruiting
Beersheva Mental Health Center
Phase 2
15
Beersheba
2024-11-25
Recruiting
Hadassah Medical Organization
Not applicable
500
Afula, Beersheba, Jerusalem, Kfar Saba, Tel HaShomer
2024-09-30
Recruiting
AbbVie
Phase 2
590
Holon, Beersheba, Tel Aviv, Haifa
2024-09-04
Active, closed
Sanofi
Phase 2
229
Afula, Beersheba, Jerusalem, Petah Tikva, Ramat HaSharon, Rehovot
2024-08-29
Recruiting
Bayer
Phase 3
444
Ashdod, Beersheba, Jerusalem, Tel Aviv
2024-08-28
Active, closed
AbbVie
Phase 3
699
Petah Tikva, Afula, Jerusalem, Beersheba, Ramat Gan
2024-08-19
Active, closed
Hoffmann-La Roche
Phase 4
19
Beersheba, Petah Tikva, Tel Aviv
2024-08-14
Recruiting
Yale University
Phase 3
124
Beersheba
2024-08-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2024-06-24
Recruiting
Eli Lilly and Company
Phase 3
300
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2024-06-03
Active, closed
Highlight Therapeutics
Phase 2
50
Beersheba, Haifa, Jerusalem, Rehovot
2024-05-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,800
Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Tel Aviv, Tel HaShomer
2024-05-24
Active, closed
Sanofi
Phase 3
1,541
Afula, Beersheba, Haifa, Jerusalem, Petah Tikva
2024-05-08
Recruiting
AstraZeneca
Phase 3
3,850
Afula, Ashkelon, Beersheba, Be’er Ya‘aqov, Haifa, Holon, Jerusalem, Kfar Saba
2024-04-12
Active, closed
Takeda
Phase 2
213
Ashdod, Beersheba, Jerusalem, Ramat Gan
2024-03-29
Active, closed
AbbVie
Phase 2
156
Tsrifin, Jerusalem, Beersheba, Ramat Gan, Tel Aviv, Petah Tikva
2024-03-23
Active, closed
Eli Lilly and Company
Phase 3
320
Atlit, Beersheba, Herzliya, Holon, Jerusalem, Ramat Gan, Sakhnin
2024-03-15
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Beersheba, Be’er Ya‘aqov, Jerusalem, Petah Tikva, Rehovot
2024-03-13
Recruiting
Eli Lilly and Company
Phase 3
90
Beersheba, Israel, Jerusalem, Petah Tikva, Rehovot
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Beersheba, Haifa, Jerusalem, Petah Tikva, Tel Aviv
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv
2024-03-07
Recruiting
Takeda
Phase 2
268
Ashdod, Beersheba, Jerusalem, Kfar Saba, Ramat Gan
2024-03-05
Active, closed
Eli Lilly and Company
Phase 3
17,300
Afula, Beersheba, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Petah Tikva
2024-03-05
Active, closed
Sanofi
Phase 3
464
Beersheba, Ramat Gan, Tel Aviv
2024-02-29
Active, closed
Novartis Pharmaceuticals
Phase 3
1,464
Beersheba, Petah Tikva, Ramat Gan, Tel Aviv
2024-02-28
Recruiting
Neurothera Labs Inc.
Not applicable
60
Beersheba
2024-02-21
Recruiting
Pfizer
Phase 3
492
Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv
2024-02-08
Active, closed
Genmab
Phase 3
1,095
Kfar Saba, Petah Tikva, Afula, Jerusalem, Beersheba, Ramat Gan, Tel Aviv
2024-02-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2023-12-31
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Jerusalem, Beersheba, Haifa, Petah Tikva, Tel Aviv
2023-11-14
Recruiting
Rambam Health Care Campus
Not applicable
1,180
Beersheba, Be’er Ya‘aqov, Haifa, Holon
2023-11-14
Active, closed
Bristol-Myers Squibb
Phase 2
227
Jerusalem, Beersheba, Be’er Ya‘aqov, Haifa, Petah Tikva, Rehovot, Safed
2023-11-07
Recruiting
LeonaBio
Phase 3
600
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv
2023-10-31
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Rehovot, Beersheba, Haifa, Be’er Ya‘aqov, Tel Aviv, Jerusalem, Petah Tikva
2023-10-25
Active, closed
Celgene
Phase 3
79
Petah Tikva, Ramat Gan, Beersheba, Tel Aviv, Haifa, Jerusalem
2023-10-16
Active, closed
Eli Lilly and Company
Phase 3
160
Beer Yaacov, Petah Tikva, Ramat Gan, Jerusalem, Afula, Haifa, Beersheba
2023-10-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Ashkelon, Beersheba, Hadera, Haifa, Herzliya, Holon, Jerusalem, Majd el Kurūm
2023-10-09
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Jerusalem, Ramat Gan, Beersheba, Hafia, Kefar Sava, Petah Tikva, Tel Aviv
2023-09-22
Recruiting
Accelerated Rotational Field Deep TMS for Treating OCD
NCT07116785Obsessive-Compulsive Disorder
Ben-Gurion University of the Negev
Not applicable
50
Beersheba
2023-09-19
Recruiting
Biotest
Phase 3
590
Beersheba, Haifa, Petah Tikva, Rehovot, Rishon LeZiyyon, Tel Aviv
2023-09-09
Active, closed
Boehringer Ingelheim
Phase 2
268
Beersheba, Haifa, Jerusalem, Tel Aviv
2023-09-08
Recruiting
Gilead Sciences
Phase 3
402
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2023-09-07
Recruiting
Tel-Aviv Sourasky Medical Center
Observational
2,000
Beersheba, Haifa, Petah Tikva, Tel Aviv
2023-09-05
Recruiting
Soroka University Medical Center
Phase 2
80
Beersheba, Petah Tikva
2023-09-01
Recruiting
Ipsen
Phase 3
276
Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva
2023-08-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Ashkelon, Beersheba, Haifa, Jerusalem, Petach Tikvah, Petah Tikva, Rehovot, Tel Aviv
2023-08-30
Recruiting
Soroka University Medical Center
Not applicable
200
Beersheba, Haifa, Petah Tikva, Ramat Gan
2023-08-01
Active, closed
Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH
NCT04627701Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
ProArc Medical
Not applicable
26
Beersheba, Haifa
2023-07-23
Recruiting
Treatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation
NCT07105475Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders, Prefrontal Cortex Dysregulation, Cortical Arousal Imbalance
Ben-Gurion University of the Negev
Not applicable
90
Beersheba
2023-07-19
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Beersheba, Holon, Ramat Gan, Be’er Ya‘aqov, Tel Aviv
2023-07-06
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Beersheba, Jerusalem, Tel Aviv
2023-06-30
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Ashdod, Ashkelon, Beersheba, Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Petach Tiqwa
2023-06-28
Active, closed
Exact Sciences Corporation
Observational
416
Tel Aviv Yaffo, Hadera, Beersheba, Afula, Jerusalem
2023-06-20
Recruiting
GlaxoSmithKline
Phase 1/2
123
Beersheba, Jerusalem, Ramat Gan
2023-06-14
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Beersheba, Haifa, Jerusalem
2023-06-01
Recruiting
Takeda
Phase 3
240
Jerusalem, Beersheba, Haifa, Petah Tikva
2023-05-16
Recruiting
Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
NCT05599347Crohn's Disease Relapse, Biological Substance; Adverse Effect
Rambam Health Care Campus
Phase 2
180
Haifa, Beersheba, Holon, Jerusalem, Kiryat Bialik, Petah Tikva
2023-04-24
Recruiting
Carmel Medical Center
Not applicable
264
Ashdod, Beersheba, Be’er Ya‘aqov, Haifa, Petah Tikva, Rehovot, Safed, Tel Aviv
2023-04-17
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Holon, Beersheba, Haifa, Jerusalem, Nahariya, Poria – Neve Oved, Ramat Gan, Rehovot
2023-03-09
Recruiting
Ben-Gurion University of the Negev
Not applicable
270
Beersheba
2023-03-09
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Beersheba, Haifa, Jerusalem, Naharya, Petah Tikva, Ramat Gan, Safed, Tel Aviv
2023-02-15
Active, closed
Areteia Therapeutics
Phase 3
600
Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2023-01-30
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Ramat Gan, Beersheba, Haifa, Jerusalem, Petah Tikva, Petah Tikvah, Tel Aviv
2023-01-23
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
Afula, Beersheba
2023-01-11
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Beersheba, Haifa, Jerusalem, Kfar Saba
2022-12-29
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Afula, Ashkelon, Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba
2022-12-27
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
885
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
2022-12-13
Recruiting
AstraZeneca
Phase 3
3,527
Afula, Ashkelon, Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan
2022-12-13
Active, closed
Pfizer
Phase 1
148
Petah Tikva, Ramat Gan, Jerusalem, Beersheba
2022-11-30
Recruiting
Pfizer
Phase 3
1,060
Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv
2022-11-10
Recruiting
Bayer
Phase 3
100
Beersheba, Jerusalem, Nahariya, Petah Tikva, Tel Aviv
2022-11-08
Recruiting
Pfizer
Observational
12,500
Afula, Beersheba, Kfar Saba, Tel Aviv
2022-10-27
Active, closed
Hoffmann-La Roche
Phase 1
121
Beersheba, Haifa, Jerusalem, Ramat Gan, Tel Aviv
2022-10-26
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-10-25
Recruiting
European Myeloma Network B.V.
Phase 3
1,594
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-09-08
Recruiting
Takeda
Phase 3
440
Beer Yaacov, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-08-24
Active, closed
Sanofi
Phase 2/3
1,856
Afula, Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-08-22
Active, closed
AbbVie
Observational
785
Beer Ya'akov, Haifa, Beersheba, Tel Aviv, Petah Tikva
2022-08-15
Active, closed
Novo Nordisk A/S
Phase 3
412
Beersheba, Haifa, Petah Tikva, Tel HaShomer, Tsrifin
2022-08-10
Active, closed
Gilead Sciences
Phase 3
443
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv
2022-07-25
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Afula, Beersheba, Haifa, Jerusalem, Nahariya, Ramat Gan
2022-07-21
Active, closed
Incyte Corporation
Phase 1/2
53
Beersheba, Be’er Ya‘aqov, Haifa, Jerusalem, Safed
2022-07-19
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Beersheba, Ramat Gan, Tel Aviv
2022-07-13
Active, closed
IO Biotech
Phase 3
407
Afula, Beersheba, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2022-05-17
Recruiting
SK Life Science, Inc.
Phase 3
252
Tel Aviv, Beersheba, Jerusalem, Ramat Gan
2022-04-28
Active, closed
Hoffmann-La Roche
Phase 3
208
Beersheba, Tel Aviv
2022-04-25
Active, closed
Bayer
Phase 3
219
Petah Tikva, Nahariya, Beersheba, Jerusalem, Tel Aviv
2022-03-28
Active, closed
Pfizer
Phase 3
854
Petah Tikva, Ramat Gan, Jerusalem, Haifa, Beersheba, Tel Aviv
2022-03-25
Recruiting
AbbVie
Phase 3
768
Safed, Beersheba, Holon, Tel Aviv
2022-03-25
Active, closed
Cordio Medical
Observational
216
Ashkelon, Beersheba, Petah Tikva
2022-03-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-03-15
Active, closed
Eli Lilly and Company
Phase 3
368
Kfar Saba, Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv
2022-03-11
Recruiting
Cordio Medical
Observational
500
Ashdod, Beersheba, Haifa, Jerusalem, Nahariya, Tel Aviv, Tiberias
2022-02-11
Recruiting
Takeda
Phase 3
120
Petah Tikva, Jerusalem, Beersheba, Haifa
2022-02-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Beersheba, Haifa, Holon, Jerusalem, Ramat Gan
2022-02-03
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Afula, Beersheba, Ramat Gan, Rehovot, Tzrifin
2022-01-19
Recruiting
Low Dose Antenatal Corticosteroids for Late Preterm Delivery
NCT05698966Respiratory Morbidity, Preterm Labor
Rambam Health Care Campus
Not applicable
1,510
Afula, Ashkelon, Beersheba, Hadera, Haifa, Jerusalem, Kfar Saba, Nahariya
2022-01-01
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Beersheba, Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tsrifin
2021-12-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Afula, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2021-12-13
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2021-11-17
Active, closed
Gilead Sciences
Phase 3
603
Ashdod, Beersheba, Jerusalem, Rehovot, Tel Aviv, Tzrifin
2021-11-17
Active, closed
AstraZeneca
Phase 3
98
Beersheba, Jerusalem, Kfar Saba, Tel Aviv, Tel HaShomer
2021-09-12
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Beer Jacob, Beersheba, Ramat Gan, Tel Aviv
2021-08-27
Active, closed
Inventiva Pharma
Phase 3
1,000
Tel Aviv, Haifa, Jerusalem, Nahariya, Beersheba, Ramat Gan
2021-08-19
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Petah Tikva
2021-08-14
Active, closed
AstraZeneca
Phase 3
315
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan
2021-06-30
Active, closed
GlaxoSmithKline
Phase 3
40
Beersheba, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv
2021-06-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Ashdod, Beersheba, Haifa, Ramat Gan, Tel Aviv
2021-06-18
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Beersheba, Haifa, Jerusalem, Petah Tikva, Tsrifin
2021-05-26
Active, closed
Incyte Corporation
Phase 3
899
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2021-05-11
Active, closed
AbbVie
Observational
141
Rehovot, Afula, Jerusalem, Safed, Ashkelon, Beersheba, Ramat Gan, Tel Aviv
2021-04-26
Active, closed
Geron Corporation
Phase 3
327
Rehovot, Tsrifin, Jerusalem, Ashdod, Ashkelon, Beersheba, Haifa
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Beersheba, Be’er Ya‘aqov, Haifa, Holon, Jerusalem, Nahariya, Petah Tikva, Tel Aviv
2021-04-09
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Afula, Beersheba, Haifa, Jerusalem, Ramat Gan, Rehovot, Tel Aviv
2021-04-05
Recruiting
Rabin Medical Center
Observational
50,000
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2021-04-01
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2021-03-22
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Petah Tikva, Beersheba, Netanya, Tel Aviv, Haifa
2021-03-09
Active, closed
German CLL Study Group
Phase 3
897
Beersheba, Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan
2021-03-01
Active, closed
Pfizer
Phase 3
257
Beersheba, Jerusalem
2021-01-15
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
548
Ramat Gan, Beersheba, Haifa, Jerusalem, Tel Aviv
2020-12-21
Active, closed
Neurocrine Biosciences
Phase 3
182
Afula, Beersheba, Petah Tikva, Tel Aviv
2020-12-16
Active, closed
Daiichi Sankyo
Phase 3
1,600
Beersheba, Ramat Gan, Jerusalem, Petah Tikva
2020-12-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Afula, Bat Galim, Beersheba, Holon, Jerusalem, Rehovot, Tel Aviv, Zsfat
2020-12-02
Active, closed
Bayer
Phase 3
402
Beersheba, Petah Tikva, Safed
2020-10-20
Active, closed
Acerta Pharma BV
Phase 3
611
Afula, Ashdod, Beersheba, Haifa, Holon, Jerusalem, Nahariya, Petah Tikva
2020-10-08
Active, closed
AbbVie
Phase 3
527
Tsrifin, Jerusalem, Ashkelon, Beersheba, Ramat Gan, Tel Aviv, Petah Tikva
2020-09-30
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Afula, Beersheba, Haifa, Jerusalem, Petach Tikvah, Ramat Gan, Tel Aviv
2020-09-23
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Ashdod, Beersheba, Be’er Ya‘aqov, Haifa, Petah Tikva, Tel Aviv
2020-09-16
Active, closed
Karyopharm Therapeutics Inc
Phase 2/3
501
Ashdod, Beersheba, Petah Tikva, Tel Aviv
2020-09-03
Recruiting
Efficacy and Safety of the CG-100 Intraluminal Bypass Device
NCT04184973Rectal Cancer, Rectal Tumor, Rectal/Anal
Colospan Ltd.
Not applicable
250
Beersheba
2020-06-23
Active, closed
Eli Lilly and Company
Phase 3
996
Ramat Gan, Rehovot, Tsrifin, Jerusalem, Nahariya, Beersheba
2020-06-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2020-05-19
Active, closed
AstraZeneca
Phase 3
818
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2020-04-16
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Beersheba, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv
2020-03-30
Active, closed
Eli Lilly and Company
Phase 3
261
Beersheba, Jerusalem, Ramat Gan, Haifa
2020-02-17
Recruiting
Merck Sharp & Dohme LLC
Observational
1,065
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
450
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-12-19
Active, closed
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
NCT04014205Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
DrugOrelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
81
Beersheba, Haifa
2019-11-18
Active, closed
Soroka University Medical Center
Not applicable
40
Beersheba
2019-11-10
Active, closed
AstraZeneca
Phase 3
140
Ashkelon, Beersheba, Jerusalem, Ramat Gan, Rehovot, Tel Aviv
2019-10-29
Active, closed
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
OncoHost Ltd.
Observational
10,000
Afula, Ashkelon, Beersheba, Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Petah Tikva
2019-10-01
Recruiting
University Hospital Muenster
Phase 3
683
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2019-08-23
Active, closed
Sanofi
Observational
1,860
Beersheba, Haifa, Kefar Sava, Ramat Gan, Rehovot
2019-08-15
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Afula, Beersheba, Haifa, Jerusalem, Kiryat Tzanz, Petach Tikvah, Tel Aviv
2019-08-15
Active, closed
AbbVie
Observational
100
Kfar Saba, Tel Aviv, Afula, Jerusalem, Safed, Beersheba, Ramat Gan, Haifa
2019-08-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-07-24
Active, closed
Tesaro, Inc.
Phase 3
785
Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv
2019-07-18
Active, closed
Exelixis
Phase 3
855
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2019-06-25
Recruiting
Rambam Health Care Campus
Phase 4
1,084
Haifa, Beersheba, Jerusalem, Kfar Saba, Netanya, Petah Tikva, Tel Aviv
2019-05-01
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Ramat Gan, Afula, Beersheba, Haifa, Jerusalem, Nahariya, Nazareth, Petah Tikva
2019-03-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Afula, Ashdod, Beersheba, Haifa, Jerusalem, Kfar Saba, Nazareth, Petah Tikva
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Beersheba, Haifa, Jerusalem, Ramat Gan, Tel Aviv
2018-12-12
Active, closed
AbbVie
Phase 3
265
Haifa, Jerusalem, Ashdod, Beersheba, Ramat Gan, Tel Aviv, Petah Tikva
2018-10-22
Active, closed
Tesaro, Inc.
Phase 3
1,400
Beersheba, Haifa, Holon, Petah Tikva, Rehovot
2018-10-11
Active, closed
AbbVie
Phase 2
270
Kfar Saba, Beersheba, Ramat Gan, Haifa, Petah Tikva
2018-10-10
Recruiting
Novartis Pharmaceuticals
Observational
700
Beersheba, Holon, Petah Tikva
2018-09-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Beersheba, Tel Aviv, Afula, Haifa, Jerusalem, Ramat Gan, Tsrifin
2018-09-12
Active, closed
AbbVie
Phase 3
1,242
Jerusalem, Beersheba, Ramat Gan, Haifa, Petah Tikva
2018-08-28
Active, closed
AbbVie
Phase 3
1,533
Beersheba, Ramat Gan, Tel Aviv, Afula, Petah Tikva
2018-08-09
Recruiting
Celgene
Phase 2/3
1,541
Beersheba, Jerusalem, Tel Aviv, Tel HaShomer
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
1,058
Beersheba, Jerusalem, Nahariya, Rehovot, Tel Aviv, Tsrifin
2018-07-18
Recruiting
Martin Schrappe
Phase 3
5,000
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2018-07-15
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Ashdod, Beersheba, Holon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel HaShomer
2018-05-14
Active, closed
AbbVie
Phase 3
1,336
Jerusalem, Beersheba, Holon, Ramat Gan, Tel Aviv, Haifa
2018-04-09
Active, closed
AbbVie
Phase 3
747
Rehovot, Tsrifin, Jerusalem, Ashkelon, Beersheba, Tel Aviv, Petah Tikva
2018-03-21
Active, closed
Janssen Research & Development, LLC
Phase 2
136
Beer Yaakov, Beersheba, Haifa, Petah Tikva, Ramat Gan
2018-03-02
Recruiting
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
DrugsEmavusertib·Ibrutinib
Curis, Inc.
Phase 1/2
152
Beersheba, Haifa, Jerusalem
2017-12-28
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Beersheba, Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2017-09-22
Active, closed
Eli Lilly and Company
Phase 3
5,637
Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tsrifin, Jerusalem, Beersheba, Haifa
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
Ramat Gan, Jerusalem, Beersheba
2017-05-02
Active, closed
AbbVie
Phase 3
950
Jerusalem, Beersheba, Haifa
2017-01-31
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Beersheba, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv
2016-09-13
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beersheba, Haifa, Holon, Kfar Saba, Petah Tikva, Ramat Gan, Zrifin
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beer Yaakov, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2015-11-19
Active, closed
AstraZeneca
Phase 3
953
Beersheba, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan
2015-11-03
Active, closed
AstraZeneca
Phase 3
682
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2015-10-21
Active, closed
Acerta Pharma BV
Phase 3
535
Ashkelon, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikvah, Rehovot, Tel Aviv
2015-06-26
Active, closed
Janssen Research & Development, LLC
Phase 2
239
Beer Yaakov, Beersheba, Haifa, Kfar Saba, Petah Tikva, Tel Aviv
2015-04-22
Active, closed
Eli Lilly and Company
Phase 3
493
Petah Tikva, Ramat Gan, Rehovot, Jerusalem, Beersheba, Kfar Saba, Tel Aviv, Haifa
2014-11-06
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2014-11
Active, closed
Eli Lilly and Company
Phase 3
453
Beersheba, Holon, Jerusalem, Kfar Saba, Petah Tikva, Tel HaShomer
2014-10-03
Active, closed
AstraZeneca
Phase 3
510
Beersheba, Haifa, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2013-09-25
Active, closed
MedImmune LLC
Phase 2
571
Beersheba
2013-05-17
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Beersheba
2013-03-18
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Ashkelon, Beersheba, Jerusalem, Ramat Gan
2012-01
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Afula, Beersheba, Haifa, Netivot, Petah Tikva, Ramat Gan, Tel Aviv
2007-06-21
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Beersheba, Haifa, Tel Aviv
2004-09-15
Recruiting
Medtronic
Observational
20,000
Ashkelon, Beersheba, Jerusalem, Ramat Gan
1983-01
Rows per page Showing 1–252 of 252
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-israel/city/beersheba

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,438 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 252 of those studies with a site in Beersheba.

How many clinical trials are recruiting in Beersheba?

109 of the 252 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 137 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beersheba), 252 studies
PhaseStudiesRecruitingShare
Phase 31505959.5%
Phase 2331413.1%
Observational22118.7%
Not applicable20137.9%
Phase 1/21154.4%
Phase 2/31154.4%
Phase 1311.2%
Phase 4210.8%

Most active sponsors

Lead sponsors with the most studies (Beersheba)
Lead sponsorStudiesRecruiting
Eli Lilly and Company219
Merck Sharp & Dohme LLC196
AbbVie183
AstraZeneca136
Hoffmann-La Roche123
Novartis Pharmaceuticals125
Janssen Research & Development, LLC114
Sanofi72
Bristol-Myers Squibb63
Pfizer63
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.